Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

520
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
520
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

557
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
557

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

At the Edge of Survival: Lessons From Extracorporeal Membrane Oxygenation Use in Pediatric Emergency Department Cardiac Arrest.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·2026
Same author

Left Ventricular Bubbles in an Asymptomatic Pediatric Outpatient: Sound the Alarm or False Alarm?

Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners·2026
Same author

Proposed Standardized Nomenclature for Anomalous Aortic Origin of a Coronary Artery: An International Multidisciplinary Initiative.

JACC. Cardiovascular imaging·2026
Same author

A computational approach for intramural length estimation in anomalous aortic origin of a coronary artery.

Frontiers in cardiovascular medicine·2026
Same author

Berlin cannulation with an outflow interposition graft-a versatile technique.

JTCVS techniques·2026
Same author

Critical care management of right ventricular failure in pediatric left ventricular assist devices: An advanced cardiac therapies improving outcomes network (ACTION) endorsed statement.

JHLT open·2025

Related Experiment Video

Updated: Mar 30, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

12.1K

Pharmacologic Approach to Heart Failure.

Sebastian C Tume1, Jason Goldberg, Silvana Molossi

  • 1Baylor College of Medicine Department of Pediatrics, Section of Critical Care Medicine Texas Children's Hospital 6621 Fannin st. W6006 Houston, Texas, 77030. sctume@texaschildrens.org.

Current Cardiology Reviews
|November 21, 2015
PubMed
Summary

This review offers a pathophysiologic approach to managing acute heart failure, focusing on reducing congestion and improving cardiac output. It also outlines pharmacologic strategies for transitioning from acute care to chronic heart failure prevention.

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K

Related Experiment Videos

Last Updated: Mar 30, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

12.1K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure presents with diverse causes and severity.
  • Patients often exhibit congestion and reduced cardiac output.

Purpose of the Study:

  • To provide a pathophysiologic framework for acute heart failure pharmacologic management.
  • To guide the transition from acute to chronic heart failure treatment strategies.

Main Methods:

  • Review of existing literature on heart failure pathophysiology and pharmacologic therapies.
  • Synthesis of information to create a management construct.

Main Results:

  • A pathophysiologic construct for managing acute heart failure.
  • Identification of key pharmacologic therapies for acute and chronic management.

Conclusions:

  • Effective pharmacologic management of acute heart failure reduces congestion and improves cardiac output.
  • A structured approach facilitates the transition to preventative strategies for chronic heart failure.